What is PTD-DBM 1MG

PTD-DBM 1MG is a synthetic peptide studied in dermatological and cosmetic research for its powerful ability to stimulate hair follicle neogenesis and combat alopecia. It is intended exclusively for research use.

Regarding its chemical identity, PTD-DBM has a molecular formula of C131H221N43O36 and a molecular weight of 2954.4 g/mol. Its reported canonical sequence is R-R-R-Q-R-R-K-K-R-G-Y-Y-L-E-L-E-K-E. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include PTD-DBM.

Product for research use.

Mechanism of action of PTD-DBM

PTD-DBM acts by blocking the interaction between CXXC5 (a negative regulator) and Dishevelled (Dvl) proteins. By disrupting this interaction, it activates the Wnt/beta-catenin signaling pathway, which is the master pathway responsible for the creation of new hair follicles and the anagen (growth) phase of hair.

Pharmacokinetics and pharmacodynamics of PTD-DBM

Administered topically (often in conjunction with micro-needling), the PTD (Protein Transduction Domain) sequence allows the peptide to penetrate the scalp effectively. It acts locally within the dermal papilla cells to exert its genetic signaling effects.

Scientific evidence on PTD-DBM

The available evidence on PTD-DBM is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated in preclinical models of androgenetic alopecia and severe hair loss. In animal models, particularly when combined with Valproic Acid, it has demonstrated the ability to actually grow entirely new hair follicles (neogenesis), not just rescue dying ones.

PTD-DBM applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

PTD-DBM protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for PTD-DBM, so no trial schemes or quantities are specified.

The presentations of this product (1MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of PTD-DBM

As a general guideline for laboratory handling, lyophilized peptides such as PTD-DBM are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 1MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

PTD-DBM Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented PTD-DBM security profile

The documented safety information in open sources for PTD-DBM is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Because it is applied topically and acts locally, systemic safety concerns are minimal. However, the Wnt/beta-catenin pathway is highly mitogenic, so theoretically, prolonged overstimulation of this pathway requires careful observation regarding localized cellular hyperplasia.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

PTD-DBM in a comparative context

Compared to Minoxidil (which primarily increases blood flow) or Finasteride (which blocks DHT), PTD-DBM targets the fundamental genetic pathway of hair creation. It is one of the only compounds researched for actual follicle neogenesis.

History and development of PTD-DBM

Developed by researchers at Yonsei University in South Korea who discovered the specific inhibitory role of the CXXC5 protein in hair loss. PTD-DBM was engineered specifically to break that inhibitory bond and reactivate dormant hair growth pathways.